CurrentCignaPolicy IP0722

Niktimvo

Defines Cigna's prior authorization, coverage criteria, dosing, and coding for Niktimvo (axatilimab-csfr) intravenous infusion for treatment of chronic graft-versus-host disease in eligible patients.

Policy Summary

PayerCigna

PolicyNiktimvo

Policy CodePolicy IP0722

Change TypeNew policy with material revisions

Effective DateAug 1, 2025

Next Review DateN/A

Key ActionObtain prior authorization and submit documentation that patient meets criteria (diagnosis, weight, prior therapies, dosing, and benefit for continuation).

SourceLink

POLICY UPDATE CHANGES

New policy created for Niktimvo for graft-versus-host disease.

For initial therapy, requirement that a patient tried two systemic treatments: the term 'conventional' was removed and 'therapies' was changed to 'medications.'

An etanercept product was added to the note listing examples of systemic therapy for chronic GVHD.

Removed 'for 1 year' under both Initial Therapy and Patient currently receiving Niktimvo sections.

≥40 kgminimum patient weight for eligibility

≥2prior systemic medications required for initial therapy

0.3 mg/kg q2wkdosing (max 35 mg per dose)

J9038primary HCPCS code listed

Coverage Criteria for Niktimvo (axatilimab-csfr)

Initial and Continuation Therapy

Approve for graft-versus-host disease when ONE of the following is met:

Approval pathways: A) Initial Therapy OR B) Patient currently receiving Niktimvo

Approvals provided for the duration noted in policy

A) Initial Therapy: Patient is ≥ 40 kg; AND patient has chronic graft-versus-host disease; AND patient has tried at least two systemic medications for chronic GVHD

Examples of systemic therapies are listed in the policy (e.g., ruxolitinib, belumosudil, ibrutinib, imatinib, hydroxychloroquine, methotrexate, rituximab, pentostatin, interleukin-2, corticosteroids, calcineurin inhibitors, sirolimus, etanercept, mycophenolate)

B) Patient currently receiving Niktimvo: Prescriber documents the patient demonstrates a beneficial clinical response (examples include reduction in corticosteroid dose, disease stabilization, and/or symptomatic improvement)

Policy Summary

PayerCigna

PolicyNiktimvo

Policy CodePolicy IP0722

Change TypeNew policy with material revisions

Effective DateAug 1, 2025

Next Review DateN/A

Key ActionObtain prior authorization and submit documentation that patient meets criteria (diagnosis, weight, prior therapies, dosing, and benefit for continuation).

SourceLink

On This Page

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Continuation approvals allowed if criteria and dosing are met

This policy defines coverage for Niktimvo (axatilimab-csfr) specifically for the treatment of chronic graft-versus-host disease (GVHD) after documented failure of prior systemic therapy. Approval is granted when ONE of the following pathways is met: either Initial Therapy — the patient is at least 40 kg, has a diagnosis of chronic GVHD, and has tried and failed at least two prior systemic medications for chronic GVHD — or Patient currently receiving Niktimvo — the prescriber documents a beneficial clinical response (for example, reduction in corticosteroid dose, disease stabilization, or symptomatic improvement). Approvals are provided for the duration noted in the policy and are contingent on meeting the dosing and monitoring requirements.

Prior authorization is required prior to benefit coverage; providers must submit documentation of diagnosis, prior therapies, patient weight, prescribed dosing (see dosing criteria), and, for continuation requests, evidence of clinical benefit. Claims submitted without the required covered diagnosis or procedure codes, or without supporting documentation that the patient meets policy criteria, may be denied as not covered.

Not Medically Necessary: Use of Niktimvo for any indication other than chronic graft-versus-host disease after failure of at least two prior systemic therapies is considered not medically necessary.

Dosing and Regimens

Regimen	Indication / Eligible Population	Dosing and Administration	Continuation Criteria
0.3 mg/kg IV infusion every 2 weeks (maximum 35 mg per dose)
Treatment of chronic graft-versus-host disease in patients weighing ≥ 40 kg after failure of at least two prior systemic medications for chronic GVHD
0.3 mg/kg IV given once every 2 weeks; maximum single dose 35 mg
Continuation allowed if prescriber documents a beneficial clinical response (e.g., reduction in corticosteroid dose, disease stabilization, and/or symptomatic improvement)

Coding and Billing

Considered Medically Necessary when criteria metHCPCSCovered

J9038

Injection, axatilimab-csfr, 0.1 mg

Minimum patient weight — eligibility

Eligibility weightPatient weight ≥ 40 kg

FDA-indication contextApproved for chronic graft‑versus‑host disease after failure of at least two prior systemic therapies

Use populationAdults and pediatric patients meeting weight and prior-therapy criteria

Provider Actions and Prior Authorization

Prior Authorization

Prior Authorization Required

Prior Authorization is required for benefit coverage of Niktimvo. Approvals are recommended when the patient meets the policy Criteria and Dosing for the indicated use. Extended approvals may be granted if the patient continues to meet criteria. Requests for doses outside the dosing documented in this policy will be reviewed case-by-case by a clinician (Medical Director or Pharmacist).

Prior Authorization required for Niktimvo (policy IP0722).
Approvals recommended when criteria and dosing are met; extended approvals allowed.
Off-label or non-standard dosing requests reviewed individually by clinician.

Step Therapy

Initial therapy prior-treatment requirement

Initial therapy approvals require that the patient have trialed and failed at least two prior systemic medications for chronic graft-versus-host disease. The patient must also meet the other initial-therapy elements (age ≥ 40 kg and diagnosis of chronic GVHD).

Initial therapy requires trial/failure of ≥ 2 systemic medications for chronic GVHD.
Patient must be ≥ 40 kg and have chronic graft-versus-host disease to qualify for initial therapy approval.

Documentation Required

Documentation submission requirements

Providers must submit documentation that the patient meets the policy criteria, including: diagnosis of chronic graft-versus-host disease, weight (to confirm ≥ 40 kg), prior treatment history demonstrating trials of at least two systemic therapies, and dosing information or prescriber statement of clinical response for continuation requests. For continuation/ongoing therapy, include documentation of beneficial clinical response (e.g., corticosteroid dose reduction, disease stabilization, symptomatic improvement).

Include diagnosis and weight documentation.
Provide records of prior systemic therapies (names, dates, outcomes) showing ≥ 2 trials for initial therapy.
For current Niktimvo therapy, provide clinician documentation of beneficial response.

Denial Risk

Claims denial risk

Claims submitted without a covered diagnosis or procedure code, or lacking required supporting documentation (diagnosis, weight, prior-treatment records, or evidence of response), will be denied as not covered. Failure to obtain prior authorization when required may result in claim denial.

Claims lacking covered diagnosis/procedure codes will be denied.
Missing required supporting documentation (prior treatments, weight, clinical response) risks denial.
Failure to obtain required prior authorization may result in denial of benefit coverage.

Line of Therapy / Salvage Use

Salvage

Salvage: Used after failure of at least two prior systemic medications for chronic GVHD; listed among subsequent-line therapy options in NCCN guidance; Niktimvo has a category 2A recommendation in NCCN Hematopoietic Cell Transplantation guidelines

Examples of prior systemic medications are provided in policy

Background

Niktimvo (axatilimab-csfr) is a colony stimulating factor‑1 receptor (CSF‑1R) blocking monoclonal antibody. It is FDA‑indicated for the treatment of chronic graft‑versus‑host disease (GVHD) in adults and pediatric patients weighing at least 40 kg who have had an inadequate response to or intolerance of at least two prior systemic therapies. The recommended regimen in this policy is 0.3 mg/kg IV every 2 weeks (maximum 35 mg per dose), with continuation allowed when the prescriber documents a beneficial clinical response (examples include corticosteroid dose reduction, disease stabilization, or symptomatic improvement).

Definitions

Definition of chronic graft‑versus‑host disease

DefinitionChronic graft‑versus‑host disease (GVHD) is an immune‑mediated complication following allogeneic hematopoietic cell transplantation that can cause multi‑organ involvement and is treated with systemic immunosuppressive agents.

Clinical contextNiktimvo is indicated for chronic GVHD after failure of at least two prior systemic therapies; examples of systemic therapies are listed in the policy.

Examples of clinical benefit used for continuationBeneficial response may include reduction in corticosteroid dose, disease stabilization, and/or symptomatic improvement.